Product Data Sheet

Product Name: Fenofibrate-d6
Cat. No.: GC47337

Chemical Properties

Cas. No.	1092484-56-4		
SMILES	ClC1=CC=C(C(C2=CC=C(OC(C([2H])([2H])[2H])(C(OC(C)C)=O)C([2H])([2H])[2H])C=C2)=O)C=C1		
Formula	C20H15ClD6O4	M.Wt	366.9
Solubility	DMF: 30 mg/ml,DMSO: 15 mg/ml,Ethanol: 1 mg/ml	Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure			

Background

Fenofibrate-d_6 is intended for use as an internal standard for the quantification of fenofibrate by GC- or LC-MS. Fenofibrate is an agonist of peroxisome proliferator-activated receptor α (PPARα) with EC_{50} values of 18 and 30 μM for mouse and human receptors, respectively, in a transactivation assay.[1] It is selective for PPARα over PPARγ (EC_{50}s = 300 and 200 μM for mouse and human receptors, respectively) and lacks activity at mouse and human PPARδ at a concentration of 100 μM. *In vivo*, fenofibrate (50-100 mg/kg) reduces plasma levels of triglycerides, C-reactive protein, and malondialdehyde (MDA) in mice with fructose-induced hypertriglycemia in a dose-dependent manner.[2] It decreases glomerular and tubular atrophy and necrosis induced by cisplatin in rat kidney when administered at a dose of 100 mg/kg.[3] Fenofibrate also reduces the number of pulmonary lesions induced by 4-nitroquinoline 1-oxide (4-NQO) in lung of Tsumura Suzuki obese diabetic (TSOD) mice.[4]

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

1.Willson, T.M., Brown, P.J., Sternbach, D.D., et al.The PPARs: From orphan receptors to drug discoveryJ. Med. Chem.43(4)527-550(2000) 2.Sun, B., Xie, Y., Jiang, J., et al.Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemiaLipids Health Dis.14:27(2015) 3.Helmy, M.M., Helmy, M.W., and El-Mas, M.M.Additive renoprotection by pioglitazone and fenofibrate against inflammatory, oxidative and apoptotic manifestations of cisplatin nephrotoxicity: Modulation by PPARsPLoS One10(11)e0142303(2015) 4.Kuno, T., Hata, K., Takamatsu, M., et al.The peroxisome proliferator-activated receptor (PPAR) α agonist fenofibrate suppresses chemically induced lung alveolar proliferative lesions in male obese hyperlipidemic miceInt. J. Mol. Sci.15(5)9160-9172(2014)

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA